Digoxin
From Free net encyclopedia
|
Image:Digoxin.png | |
| 3-((O-2,6-dideoxy-β-D-ribo-hexopyranosyl- (1-4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl- (1-4)-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy)- 12,14-dihydroxy-,(3β,5β,12β)-card-20(22)-enolide | |
| CAS number 20830-75-5 | ATC code C01AA05 |
| Chemical formula | C41H64O14 |
| Molecular weight | 780.943 |
| Bioavailability | ~75% |
| Metabolism | Hepatic (16%) |
| Elimination half-life | 36 hours |
| Excretion | ~70% renal unchanged |
| Pregnancy category | Category C |
| Legal status | POM (UK) |
| Routes of administration | oral, intravenous |
Digoxin is a cardiac glycoside extracted from the foxglove plant, digitalis. It is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and congestive heart failure that cannot be controlled by other medication.
Contents |
Actions
The main effects of digoxin are on the heart, its extracardiac effects are responsible for most of the side effects, i.e. nausea, vomiting, diarrhea and confusion.
Its main cardiac effects are:
- A decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter.
- An increase of force of contraction via inhibition of the Na+/K+ ATPase pump (see below).
Mechanism of action
Digoxin binds to a site on the extracellular aspect of the α-subunit of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by digoxin. This is a different mechanism from that of catecholamines.
Digoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias (see below).
Clinical use
Today, the most common indications for digoxin are probably atrial fibrillation and atrial flutter with rapid ventricular response. High ventricular rate leads to insufficient diastolic filling time. By slowing down the conduction in the AV node and increasing its refractory period, digoxin can reduce the ventricular rate. The arrhythmia itself is not affected, but the pumping function of the heart improves owing to improved filling.
The use of digoxin in congestive heart failure during sinus rhythm is controversial. In theory the increased force of contraction should lead to improved pumping function of the heart, but its effect on prognosis is disputable and digoxin is no longer the first choice for congestive heart failure. However, it can still be useful in patients who remain symptomatic despite proper diuretic and ACE inhibitor treatment.
Digoxin is usually given by mouth, but can also be given by IV injection in urgent situations (the IV injection should be slow, heart rhythm should be monitored). The half life is about 36 hours, digoxin is given once daily, usually in 125 μg or 250 μg dosing. In patients with decreased kidney function the half life is considerably longer, calling for a reduction in dosing or a switch to a different glycoside (digitoxin).
Effective plasma levels are fairly well defined, 1-2.6 nmol/l. In suspected toxicity or ineffectiveness, digoxin levels should be monitored. Plasma potassium levels also need to be closely controlled (see side effects below).
Side effects
Owing to its narrow therapeutic index (the margin between effectiveness and toxicity), side effects of digoxin are inevitable. Nausea, vomiting and GIT upset are common, especially in higher doses. Decreased conduction in the AV node can lead to AV blocks, increased intracellular Ca2+ causes a type of arrhytmia called bigeminy (coupled beats), eventually ventricular tachycardia or fibrillation. An often described but rarely seen side effect of digoxin is a disturbance of colour vision (mostly yellow and green colour) called xanthopsia.
Side effects of digoxin are more common in patients with low potassium levels (hypokalaemia), since digoxin normally competes with K+ ions for the same binding site on the Na+/K+ ATPase pump. However, in patients with acute digoxin toxicity with low potassium levels, potassium supplementation is contraindicated in the presence of an AV block.
Other
Digoxin has potentially dangerous interaction with verapamil and amiodarone.
In an overdose, the usual supportive measures are needed. Digoxin cannot be removed by haemodialysis, the antidote is antidigoxin (antibody fragments against digoxin, trade name Digibind®).
Some physical properties of digoxin are water solubility of 64.8 mg/L at 25 °C and melting point at 249 °C.
In the news
Charles Cullen admitted in 2003 to killing as many as 40 hospital patients with overdoses of heart medication - usually digoxin - at hospitals in New Jersey and Pennsylvania over his 16-year career as a nurse. He was scheduled to be sentenced in early January of 2006. See: http://usatoday.com/news/nation/2006-01-01-patient-deaths_x.htm
See also
References
- Rang, Dale, Ritter, Moore. Pharmacology (5th edition), Churchill Livingstone, 2003. ISBN 0443 071454
- Summary of product characteristics, Digoxin 0,125 mg, Zentiva a.s.
- Lüllmann. Pharmakologie und Toxikologie (15th edition), Georg Thieme Verlag, 2003. ISBN 3133 685155fr:Digoxine